home / stock / apvo / apvo news

APVO News and Press, Aptevo Therapeutics Inc. From 11/23/21

Stock Information
Company Name: Aptevo Therapeutics Inc.
Stock Symbol: APVO
Market: NASDAQ
Website: aptevotherapeutics.com
Menu
APVO APVO Quote APVO Short APVO News APVO Articles APVO Message Board
Get APVO Alerts

News, Short Squeeze, Breakout and More Instantly...
APVO - Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia

SEATTLE, WA / ACCESSWIRE / November 23, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform techno...
APVO - FEMY, APVO and LTRY among mid-day movers

Gainers: Longeveron (NASDAQ:LGVN) +137%. Virtuoso (NASDAQ:VOSOU) +89%. Dicerna (NASDAQ:DRNA) +79%. ClearSign (NASDAQ:CLIR) +33%. Alpine (NASDAQ:ALPP) +22%. Macy's (NYSE:M) +21%. Enthusiast Gaming Holdings (NASDAQ:EGLX) +20%. BJ's (NYSE:BJ) +19%. Jowell Global (NASDAQ:JWEL) +17%. Yatsen Holdin...

APVO - Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting

SEATTLE, WA / ACCESSWIRE / November 15, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform techno...

APVO - Aptevo Therapeutics EPS beats by $0.03, misses on revenue

Aptevo Therapeutics (NASDAQ:APVO): Q3 GAAP EPS of -$1.45 beats by $0.03. Revenue of $3.1M (+112.3% Y/Y) misses by $0.55M. Press Release For further details see: Aptevo Therapeutics EPS beats by $0.03, misses on revenue

APVO - Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights

SEATTLE, WA / ACCESSWIRE / November 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform techno...

APVO - Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021

Data support Advancement into the Clinic LUND, SWEDEN, and SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Alligator Bioscience AB (" Alligator ") and Aptevo Therapeutics ("Aptevo") today announce preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4...

APVO - Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting

Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing...
APVO - BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advan...

APVO - Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021

SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technol...

APVO - Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436

SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technol...
Previous 10 Next 10